In women with severe connective tissue diseases receiving chemotherapy, premature ovarian failure occurred in none receiving triptorelin versus five without it.
In plain wordsIn women receiving chemotherapy, ovarian failure occurred in none receiving triptorelin versus five without it.
- Outcome
- DecreasePremature ovarian failure
- Study
n = 17
- Comparator
- Similar alkylating-agent chemotherapy without GnRH agonist
- Outcome group
- Sex hormones and fertility · Reproductive and sexual health
- Studied dose
- 3.75 mg monthly · intramuscular · up to six monthsAs given in this study (human).
Measurements
- Premature ovarian failure
- 5 patients
- chemotherapy alone (n=9)
- Premature ovarian failure
- > 50%
- chemotherapy alone
Source sentences
Whereas none of the eight women receiving GnRH-a in parallel to alkylating agent chemotherapy (cyclophosphamide (7) or chlorambucil (1)) suffered POF and hypergonadotropic amenorrhea, five of the nine ( > 50%) patients treated by alkylating agents (cyclophosphamide (8) or chlorambucil (1)) experienced POF.
2 context sentences(design, population, supporting numbers)
A monthly intramuscular depot injection of 3.75 mg D-TRP6-GnRH-a (Decapeptyl C.R.) was administered after informed consent to eight women with autoimmune, severe connective tissue diseases (seven SLE patients and one woman with nephrotic syndrome) in parallel to chemotherapy, for up to six months.
These eight treated patients (study group) were compared to a group of nine women similarly treated by cyclophosphamide pulses (CPT) or chlorambucil for SLE/connective tissue disease but were not referred for the GnRH-a adjuvant treatment.